Aktuellt
SENASTE
Curasight has reported its Q3/22 quarterly report. In terms of the P&L, there is nothing to report on since it is an early-stage biotech company with zero revenue. Curasight is executing on its strategy and just recently added two more indications to its pipeline: Neuroendocrine tumours and head and neck cancer. We have long commented on this subject and refer readers who want to know more about Curasigt's expanded strategy to our previous comments.
LÄS MER
